321 related articles for article (PubMed ID: 18268007)
1. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.
Quinlan MP; Quatela SE; Philips MR; Settleman J
Mol Cell Biol; 2008 Apr; 28(8):2659-74. PubMed ID: 18268007
[TBL] [Abstract][Full Text] [Related]
2. Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion.
Quinlan MP; Settleman J
Cell Cycle; 2008 May; 7(10):1332-5. PubMed ID: 18418066
[TBL] [Abstract][Full Text] [Related]
3. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.
Kiessling MK; Oberholzer PA; Mondal C; Karpova MB; Zipser MC; Lin WM; Girardi M; Macconaill LE; Kehoe SM; Hatton C; French LE; Garraway LA; Polier G; Süss D; Klemke CD; Krammer PH; Gülow K; Dummer R
Blood; 2011 Feb; 117(8):2433-40. PubMed ID: 21209378
[TBL] [Abstract][Full Text] [Related]
4. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
Zhang J; Lodish HF
Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
[TBL] [Abstract][Full Text] [Related]
6. KRAS(G12V) enhances proliferation and initiates myelomonocytic differentiation in human stem/progenitor cells via intrinsic and extrinsic pathways.
Fatrai S; van Gosliga D; Han L; Daenen SM; Vellenga E; Schuringa JJ
J Biol Chem; 2011 Feb; 286(8):6061-70. PubMed ID: 21169357
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
8. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
10. The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras.
Oliva JL; Zarich N; Martínez N; Jorge R; Castrillo A; Azañedo M; García-Vargas S; Gutiérrez-Eisman S; Juarranz A; Boscá L; Gutkind JS; Rojas JM
J Biol Chem; 2004 Aug; 279(32):33480-91. PubMed ID: 15181015
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas.
Park SW; Davison JM; Rhee J; Hruban RH; Maitra A; Leach SD
Gastroenterology; 2008 Jun; 134(7):2080-90. PubMed ID: 18549880
[TBL] [Abstract][Full Text] [Related]
13. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
14. The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
Thompson KN; Whipple RA; Yoon JR; Lipsky M; Charpentier MS; Boggs AE; Chakrabarti KR; Bhandary L; Hessler LK; Martin SS; Vitolo MI
Oncotarget; 2015 Nov; 6(34):35231-46. PubMed ID: 26497685
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors.
Sasaki AT; Carracedo A; Locasale JW; Anastasiou D; Takeuchi K; Kahoud ER; Haviv S; Asara JM; Pandolfi PP; Cantley LC
Sci Signal; 2011 Mar; 4(163):ra13. PubMed ID: 21386094
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
Ji Z; Mei FC; Xie J; Cheng X
J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
[TBL] [Abstract][Full Text] [Related]
17. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
18. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
19. Induction of postmitotic neuroretina cell proliferation by distinct Ras downstream signaling pathways.
Peyssonnaux C; Provot S; Felder-Schmittbuhl MP; Calothy G; Eychène A
Mol Cell Biol; 2000 Oct; 20(19):7068-79. PubMed ID: 10982823
[TBL] [Abstract][Full Text] [Related]
20. Rare codons regulate KRas oncogenesis.
Lampson BL; Pershing NL; Prinz JA; Lacsina JR; Marzluff WF; Nicchitta CV; MacAlpine DM; Counter CM
Curr Biol; 2013 Jan; 23(1):70-5. PubMed ID: 23246410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]